283 related articles for article (PubMed ID: 27126835)
21. A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center.
Canadeo A; Fournogerakis M; Zook F
Curr Hematol Malig Rep; 2021 Dec; 16(6):509-516. PubMed ID: 34618316
[TBL] [Abstract][Full Text] [Related]
22. Integration of a clinical pharmacist into the hematology-oncology clinics at an academic medical center.
Valgus JM; Faso A; Gregory KM; Jarr S; Savage S; Caiola S; Walko CM; Kim J; Bernard SA
Am J Health Syst Pharm; 2011 Apr; 68(7):613-9. PubMed ID: 21411803
[TBL] [Abstract][Full Text] [Related]
23. Health-system specialty pharmacy role and outcomes: A review of current literature.
Zuckerman AD; Whelchel K; Kozlicki M; Simonyan AR; Donovan JL; Gazda NP; Mourani J; Smith AM; Young L; Ortega M; Kelley TN
Am J Health Syst Pharm; 2022 Oct; 79(21):1906-1918. PubMed ID: 35916907
[TBL] [Abstract][Full Text] [Related]
24. A clinical pharmacy pilot within a Precision Medicine Program for cancer patients and review of related pharmacist clinical practice.
Arnall JR; Petro R; Patel JN; Kennedy L
J Oncol Pharm Pract; 2019 Jan; 25(1):179-186. PubMed ID: 29078708
[TBL] [Abstract][Full Text] [Related]
25. Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic.
McKee M; Frei BL; Garcia A; Fike D; Soefje SA
J Oncol Pharm Pract; 2011 Dec; 17(4):387-94. PubMed ID: 21239453
[TBL] [Abstract][Full Text] [Related]
26. Implementation of a patient-focused specialty pharmacy program in an academic healthcare system.
Rim MH; Smith L; Kelly M
Am J Health Syst Pharm; 2016 Jun; 73(11):831-8. PubMed ID: 27126829
[TBL] [Abstract][Full Text] [Related]
27. Impact of an integrated oral chemotherapy program on patient adherence.
Morgan KP; Muluneh B; Deal AM; Amerine LB
J Oncol Pharm Pract; 2018 Jul; 24(5):332-336. PubMed ID: 28379068
[TBL] [Abstract][Full Text] [Related]
28. Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for patients and health-system pharmacists.
Kirschenbaum BE
Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S13-20. PubMed ID: 19966075
[TBL] [Abstract][Full Text] [Related]
29. Addressing the Challenges of Novel Oncology and Hematology Treatments Across Sites of Care: Specialty Pharmacy Solutions.
Wyatt H; Zuckerman AD; Hughes ME; Arnall J; Miller R
J Oncol Pharm Pract; 2022 Apr; 28(3):627-634. PubMed ID: 35037778
[No Abstract] [Full Text] [Related]
30. Impact of an innovative partnership in patient care between an academic medical center department of pharmacy and a school of pharmacy.
Vest MH; Petrovskis MG; Savage SW; Pinelli NR; Pappas AL; Morbitzer KA; Eckel SF; Rhoney DH; Rao KV
Am J Health Syst Pharm; 2019 Dec; 76(24):2070-2076. PubMed ID: 31789353
[TBL] [Abstract][Full Text] [Related]
31. Implementation and quality assessment of a pharmacy services call center for outpatient pharmacies and specialty pharmacy services in an academic health system.
Rim MH; Thomas KC; Chandramouli J; Barrus SA; Nickman NA
Am J Health Syst Pharm; 2018 May; 75(10):633-641. PubMed ID: 29610290
[TBL] [Abstract][Full Text] [Related]
32. Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting.
McBride A; Campen CJ; Camamo J; Maloney M; Persky D; Kurtin SE; Barket NL; Krishnadasan R; Elquza E; Anwer F; Weibel K
Am J Health Syst Pharm; 2018 May; 75(9):e246-e258. PubMed ID: 29691269
[TBL] [Abstract][Full Text] [Related]
33. Health-system specialty pharmacy: Overview of a hybrid clinical model.
Meadors C; McPheeters C; Maier C; O'Reilly E
Am J Health Syst Pharm; 2024 Apr; 81(9):e256-e260. PubMed ID: 38146967
[TBL] [Abstract][Full Text] [Related]
34. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Lam MS; Cheung N
J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
[TBL] [Abstract][Full Text] [Related]
35. A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
Lee C; Grigorian M; Nolan R; Binder G; Rice G
J Med Econ; 2016; 19(4):397-402. PubMed ID: 26652728
[TBL] [Abstract][Full Text] [Related]
36. Precision medicine in oncology: New practice models and roles for oncology pharmacists.
Walko C; Kiel PJ; Kolesar J
Am J Health Syst Pharm; 2016 Dec; 73(23):1935-1942. PubMed ID: 27864201
[TBL] [Abstract][Full Text] [Related]
37. New anticancer agents: role of clinical pharmacy services.
Leveque D; Delpeuch A; Gourieux B
Anticancer Res; 2014 Apr; 34(4):1573-8. PubMed ID: 24692684
[TBL] [Abstract][Full Text] [Related]
38. Development and implementation of an interdisciplinary oncology program in a community hospital.
Chung C; Collins A; Cui N
Am J Health Syst Pharm; 2011 Sep; 68(18):1740-7. PubMed ID: 21880891
[TBL] [Abstract][Full Text] [Related]
39. Impact of clinical pharmacists in outpatient oncology practices: A review.
Gatwood J; Gatwood K; Gabre E; Alexander M
Am J Health Syst Pharm; 2017 Oct; 74(19):1549-1557. PubMed ID: 28947527
[TBL] [Abstract][Full Text] [Related]
40. Development of a tool to allocate inpatient specialized pharmacy resources at a comprehensive cancer center.
Smith AT; Kennerly-Shah JM; Kusoski CL
J Oncol Pharm Pract; 2020 Oct; 26(7):1686-1694. PubMed ID: 32865162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
